Latest blog posts

Increasing the Accuracy of Multiple Sclerosis Relapse Monitoring

In the Relapsing-Remitting form of Multiple Sclerosis (RRMS), a single biomarker (soluble neurofilament light chain or sNfL) is identified as a biomarker for inflammatory activity in MS, but is limited in its ability to identify relapses. Through screening several hundred proteins using Olink® technology, three additional protein biomarkers have been identified as an improved relapse-specific signature to monitor disease activity in RRMS patients. Multiple sclerosis (MS) is a chronic autoimmune disease affecting the nervous system (brain and spinal cord) causing the degradation of myelin, the protective insulating layer around nerve fibers. By disrupting the normal signaling to and from the brain, unpredictable symptoms develop: numbness, fatigue and mood changes, all the way up to pain, paralysis and/or blindness. Nearly 1 million people in the United States and up to 2.8 million worldwide live with multiple sclerosis, which is the most common disabling disease of young adults. Current research indicates that a complex set of genetic and environmental factors play a role in its pathogenesis, including low levels of Vitamin D, infection with Epstein-Barr Virus and childhood obesity all implicated.

Developing a high-performance biomarker panel for Alzheimer’s Disease screening and staging

In a landmark study, 13 pharmaceutical companies in conjunction with researchers from the UK Biobank (UKB) present the largest open-access resource of proteomic data analyzing 1,463 proteins across 54,306 UK Biobank participants. A full 10,248 primary genetic associations were identified, of which 85% were newly discovered. This public scientific resource of unprecedented breadth and depth will uncover biological mechanisms underlying genetic discovery and test hypotheses crucial to the development of improved diagnostics and therapeutics for human disease.

Genetic Regulation of the Human Plasma Proteome in the UK Biobank

In a landmark study, 13 pharmaceutical companies in conjunction with researchers from the UK Biobank (UKB) present the largest open-access resource of proteomic data analyzing 1,463 proteins across 54,306 UK Biobank participants. A full 10,248 primary genetic associations were identified, of which 85% were newly discovered. This public scientific resource of unprecedented breadth and depth will uncover biological mechanisms underlying genetic discovery and test hypotheses crucial to the development of improved diagnostics and therapeutics for human disease.

The Importance of the Proteome by Dr. Kari Stefansson at ESHG

Titled “The Proteome as a net with which to catch environmental influences on phenotype”, Dr. Kari Stefansson the CEO of deCODE Genetics of Iceland shared a lunchtime presentation at the recent European Society for Human Genetics held in Vienna Austria.

Olink at the 2022 European Society for Human Genetics (ESHG) Conference

This year’s ESHG conference will be held June 11-14, 2022 in Vienna, Austria as both an in-person as well as virtual event; here are a few highlighted talks of interest as it relates to the combination of genetics, proteomics and other multiomic strategies for personalized medicine

Olink announces collaboration with new sequencing platform providers Element Biosciences and Singular Genomics

Two recently announced next-generation sequencing platforms offer increases in Olink Explore readout flexibility and cost-effectiveness

Speed drug development through stratifying clinical trial enrollment

Progressive fibrosing interstitial lung disease (PF-ILD) is a disease with a heterogenous phenotype and clinical trials could be vastly reduced if a biomarker stratification approach could be adopted.

Identifying predictive and prognostic biomarkers for Crohn’s disease

Highlights from live Olink-sponsored workshops in Boston.

Can inflammation biomarkers classify different forms of diabetes?

Diabetes is a complex disease characterized by a combination of different and little understood, causes.

Introducing CORAL, a neurology research consortium using Olink data

In its mission to accelerate proteomics together, Olink encourages the advancement of science through comprehensive support of its customers in their own studies to achieve better insight into their areas of research.